Loading...
Loading...
NOVN| Name | Value |
|---|---|
| Revenues | 6.2M |
| Cost of Revenue | 2.6M |
| Gross Profit | 3.5M |
| Operating Expense | 12.3M |
| Operating I/L | -8.7M |
| Other Income/Expense | -0.1M |
| Interest Income | 0.0M |
| Pretax | -8.9M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -9.0M |
Novan, Inc. is a pre-commercial pharmaceutical company specializing in nitric oxide-based dermatology and anti-infective therapies. The company's product pipeline includes topical treatments for acne vulgaris, viral skin infections, fungal infections, and inflammatory skin diseases. Additionally, Novan is developing products for the treatment of external genital warts, high-risk human papilloma virus (HPV), and SARS-CoV-2. The company generates revenue through the development and potential commercialization of these drug candidates, leveraging license agreements with Sato Pharmaceutical Co., Ltd., and a strategic alliance with Orion Corporation.
